Pricing Log in Create free account

Alzamend Neuro, Inc. (ALZN) vs VistaGen Therapeutics, Inc. (VTGN)

Alzamend Neuro, Inc. and VistaGen Therapeutics, Inc. are both Biotechnology companies. Alzamend Neuro, Inc. and VistaGen Therapeutics, Inc. are of similar size ($7.5M and $7.3M). Alzamend Neuro, Inc. has the higher net margin (0.00% vs −2,703.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Alzamend Neuro, Inc. leads on 10 and VistaGen Therapeutics, Inc. on 3.

Valuation

Metric ALZN VTGN Biotechnology median
P/E n/m n/m 10.60
P/S n/m 2.92 9.40
P/B 1.10 0.30 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.10 0.23 0.66
EV/Sales n/m (6.44) 9.02
Earnings yield (160.84%) (976.47%) (32.88%)
Free cash flow yield (111.54%) (854.68%) (23.13%)

Profitability

Metric ALZN VTGN Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (2,785.69%) 0.00%
Net margin 0.00% (2,703.72%) 0.00%
Free cash flow margin 0.00% (2,490.88%) 0.00%
Return on equity (163.23%) (166.46%) (51.96%)
Return on assets (122.36%) (129.22%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALZN VTGN Biotechnology median
Revenue growth (TTM) — 287.15% 6.76%
EPS growth (last fiscal year) 76.77% (9.58%) 29.88%
Revenue growth, 5-year CAGR — 3.10% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALZN VTGN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.01 3.07 4.97
Net debt to EBITDA 0.08 0.63 1.01

Dividend

Metric ALZN VTGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALZN VTGN Biotechnology median
Market cap 7.48m 7.33m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack